All In Biotech

Drug Trial Radar · NCT07925450

Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's Disease

Developing and Validating a Predictive Model for the Management of Iron Deficiency Anemia in Pediatric Crohn's Disease Through Analysis of Microbiome and Patient Laboratory Data

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 13, 2023

Primary completion

Mar 13, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Children and young adults with Crohn's disease may develop iron deficiency anemia, a condition in which low iron levels reduce the number of healthy red blood cells. This study aims to develop and test a model to help identify which iron treatment approached are most effective for these patients. Researchers will examine laboratory results, disease activity, treatment information, and information about bacteria in the digestive tract. Participants will be followed over time, and questionnaires will assess iron supplement use and related symptoms. The findings may help guide iron treatment for children and young adults with Crohn's disease.

Conditions

  • Crohn's Disease
  • Iron Deficiency Anemia

Interventions

  • Iron (ferrous sulfate)Drug

    Iron supplementation for treatment of iron deficiency anemia. The dose, schedule, and route are determined by the assigned study arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Hemoglobin LevelTime frame: At routine follow-up visits typically every 4 to 12 weeks, for up to 3 years after enrollment.
  2. Median MCV (Mean Corpuscular Volume)Time frame: At routine follow-up visits, typically every 4-12 weeks, for up to 3 years after enrollment.
  3. Median Serum Iron LevelTime frame: Approximately every 6 months during follow-up, for up to 3 years after enrollment.
  4. Median Iron SaturationTime frame: Approximately every 6 months during follow-up, for up to 3 years after enrollment.
  5. Median Ferritin LevelTime frame: Approximately every 6 months during follow-up for up to 3 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.